Patents by Inventor Edward L. Halk

Edward L. Halk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FULLY HUMAN ANTIBODIES AGAINST HUMAN 4-1BB
    Publication number: 20140193422
    Abstract: Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating a disease in a subject comprising administering a therapeutically effective amount of the antibody to said subject.
    Type: Application
    Filed: March 14, 2014
    Publication date: July 10, 2014
    Inventors: Maria Jure-Kunkel, Laura J. Hefta, Marc Santoro, Subinay Ganguly, Edward L. Halk
  • Fully human antibodies against human 4-1BB
    Patent number: 8716452
    Abstract: Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating a disease in a subject comprising administering a therapeutically effective amount of the antibody to said subject.
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: May 6, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Maria Jure-Kunkel, Laura J. Hefta, Marc Santoro, Subinay Ganguly, Edward L. Halk
  • FULLY HUMAN ANTIBODIES TO BTLA
    Publication number: 20140017255
    Abstract: The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.
    Type: Application
    Filed: September 19, 2013
    Publication date: January 16, 2014
    Applicant: MEDAREX, L.L.C.
    Inventors: Jennifer Marie MATARAZA, Andrea VAN ELSAS, Alan J. KORMAN, Edward L. HALK, Kent B. THUDIUM, Mark J. SELBY, Timothy W. SPROUL, Heidi N. LEBLANC
  • Fully human antibodies to BTLA
    Patent number: 8563694
    Abstract: The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.
    Type: Grant
    Filed: July 26, 2010
    Date of Patent: October 22, 2013
    Assignees: Medarex, Inc., N.V.Organon
    Inventors: Jennifer Marie Mataraza, Andrea Van Elsas, Alan J. Korman, Edward L. Halk, Kent B. Thudium, Mark Selby, Timothy W. Sproul, Heidi N. Leblanc
  • Human CTLA-4 antibodies and their uses
    Patent number: 8318916
    Abstract: The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
    Type: Grant
    Filed: August 4, 2011
    Date of Patent: November 27, 2012
    Assignee: Medarex, Inc.
    Inventors: Alan J. Korman, Edward L. Halk, Nils Lonberg, Yashwant M. Deo, Tibor P. Keler
  • Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof
    Patent number: 8263073
    Abstract: The present invention provides isolated monoclonal antibodies that bind to CTLA-4 and that are capable of increasing the response of T cells to antigenic stimulation in vivo yet the antibodies do not substantially block the binding of CTLA-4 to B7 ligands (e.g., B7-1 and B7-2) in vitro. Thus, the antibodies of the invention demonstrate that is it possible to separate the immunostimulatory function of anti-CTLA-4 antibodies from their ability to block the binding of B7 ligands. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for increasing the response of T cells to antigenic stimulation using the antibodies of the invention, including methods for treating cancer using the antibodies of the invention.
    Type: Grant
    Filed: February 4, 2009
    Date of Patent: September 11, 2012
    Assignee: Medarex, Inc.
    Inventors: Alan Korman, Edward L. Halk, Changyu Wang, Kent B. Thudium, Lan Yang, Kristopher Toy
  • FULLY HUMAN ANTIBODIES TO BTLA
    Publication number: 20120183565
    Abstract: The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.
    Type: Application
    Filed: July 26, 2010
    Publication date: July 19, 2012
    Applicants: N.V. ORGANON, MEDAREX, INC.
    Inventors: Jennifer Marie Mataraza, Andrea Van Elsas, Alan J. Korman, Edward L. Halk, Kent B. Thudium, Mark Selby, Timothy W. Sproul, Heidi N. Leblanc
  • FULLY HUMAN ANTIBODIES AGAINST HUMAN 4-1BB
    Publication number: 20120141494
    Abstract: Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating a disease in a subject comprising administering a therapeutically effective amount of the antibody to said subject.
    Type: Application
    Filed: February 8, 2012
    Publication date: June 7, 2012
    Inventors: Maria Jure-Kunkel, Laura J. Hefta, Marc Santoro, Subinay Ganguly, Edward L. Halk
  • Fully human antibodies against human 4-1BB
    Patent number: 8137667
    Abstract: Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating a disease in a subject comprising administering a therapeutically effective amount of the antibody to said subject.
    Type: Grant
    Filed: December 9, 2009
    Date of Patent: March 20, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Maria Jure-Kunkel, Laura J. Hefta, Marc Santoro, Subinay Ganguly, Edward L. Halk
  • Human CTLA-4 Antibodies And Their Uses
    Publication number: 20110296546
    Abstract: The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
    Type: Application
    Filed: August 4, 2011
    Publication date: December 1, 2011
    Inventors: Alan J. Korman, Edward L. Halk, Nils Lonberg, Yashwant M. Deo, Tibor P. Keler
  • Human CTLA-4 antibodies and their uses
    Patent number: 8017114
    Abstract: The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: September 13, 2011
    Assignee: Medarex, Inc.
    Inventors: Alan J. Korman, Edward L. Halk, Nils Lonberg, Yashwant M. Deo, Tibor P. Keler
  • ANTI-CTLA-4 ANTIBODIES WITH REDUCED BLOCKING OF BINDING OF CTLA-4 TO B7 AND USES THEREOF
    Publication number: 20110081354
    Abstract: The present invention provides isolated monoclonal antibodies that bind to CTLA-4 and that are capable of increasing the response of T cells to antigenic stimulation in vivo yet the antibodies do not substantially block the binding of CTLA-4 to B7 ligands (e.g., B7-1 and B7-2) in vitro. Thus, the antibodies of the invention demonstrate that is it possible to separate the immunostimulatory function of anti-CTLA-4 antibodies from their ability to block the binding of B7 ligands. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for increasing the response of T cells to antigenic stimulation using the antibodies of the invention, including methods for treating cancer using the antibodies of the invention.
    Type: Application
    Filed: February 4, 2009
    Publication date: April 7, 2011
    Inventors: Alan Korman, Edward L. Halk, Changyu Wang, Kent B. Thudium, Lan Yang, Kristopher Toy
  • Transgenic Trasnchromosomal Rodents for Making Human Antibodies
    Publication number: 20110003319
    Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.
    Type: Application
    Filed: September 9, 2010
    Publication date: January 6, 2011
    Applicants: KYOWA HAKKO KIRIN CO., LTD., MEDAREX, INC.
    Inventors: KAZUMA TOMIZUKA, ISAO ISHIDA, NILS LONBERG, EDWARD L. HALK
  • Transgenic transchromosomal rodents for making human antibodies
    Patent number: 7816578
    Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.
    Type: Grant
    Filed: September 30, 2005
    Date of Patent: October 19, 2010
    Assignees: Kyowa Hakko Kirin Co., Ltd., Medarex, Inc.
    Inventors: Kazuma Tomizuka, Isao Ishida, Nils Lonberg, Edward L. Halk
  • Fully human antibodies against human 4-1BB
    Publication number: 20100183621
    Abstract: Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating a disease in a subject comprising administering a therapeutically effective amount of the antibody to said subject.
    Type: Application
    Filed: December 9, 2009
    Publication date: July 22, 2010
    Inventors: Maria Jure-Kunkel, Laura J. Hefta, Marc Santoro, Subinay Ganguly, Edward L. Halk
  • Human CTLA-4 Antibodies and Their Uses
    Publication number: 20100047244
    Abstract: The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
    Type: Application
    Filed: September 22, 2009
    Publication date: February 25, 2010
    Applicant: Medarex, Inc.
    Inventors: Alan J. Korman, Edward L. Halk, Nils Lonberg, Yashwant M. Deo, Tibor P. Keler
  • Polynucleotides encoding fully human antibodies against human 4-1BB
    Patent number: 7659384
    Abstract: Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating a disease in a subject comprising administering a therapeutically effective amount of the antibody to said subject.
    Type: Grant
    Filed: September 20, 2007
    Date of Patent: February 9, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Maria Jure-Kunkel, Laura J. Hefta, Marc Santoro, Subinay Ganguly, Edward L. Halk
  • Human CTLA-4 antibodies and their uses
    Patent number: 7605238
    Abstract: The present invention provides human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
    Type: Grant
    Filed: September 7, 2001
    Date of Patent: October 20, 2009
    Assignee: Medarex, Inc.
    Inventors: Alan J. Korman, Edward L. Halk, Nils Lonberg, Yashwant M. Deo, Tibor P. Keler
  • Transgenic transchromosomal rodents for making human antibodies
    Patent number: 7576258
    Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.
    Type: Grant
    Filed: September 30, 2005
    Date of Patent: August 18, 2009
    Assignees: Medarex, Inc., Kyowa Hakko Kirin Co., Ltd.
    Inventors: Kazuma Tomizuka, Isao Ishida, Nils Lonberg, Edward L. Halk
  • Fully human antibodies against human 4-1BB
    Publication number: 20090068192
    Abstract: Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating a disease in a subject comprising administering a therapeutically effective amount of the antibody to said subject.
    Type: Application
    Filed: September 20, 2007
    Publication date: March 12, 2009
    Inventors: Maria Jure-Kunkel, Laura J. Hefta, Marc Santoro, Subinay Ganguly, Edward L. Halk